-
Pembrolizumab, sold
under the
brand name Keytruda, is a
humanized antibody, more
specifically a PD-1 inhibitor, used in
cancer immunotherapy that treats...
- Favezelimab/
pembrolizumab is a fixed-dose
combination of two
monoclonal antibodies developed by
Merck to
treat various cancers. Timmerman, John; Lavie...
- As
adjuvant therapy, mRNA-4157
monotherapy and in
combination with
pembrolizumab have been
investigated in
patients with
resected solid tumors (melanoma...
- system.
Atezolizumab is an anti PD-L1
monoclonal antibody.
Nivolumab and
Pembrolizumab are anti PD-1
monoclonal antibodies.
Ipilimumab is a
monoclonal antibody...
-
clinical and
observational studies,
immune checkpoint inhibitors (e.g.,
pembrolizumab) have been
tested in
mucosal melanomas and have
shown promising response...
-
undergoing treatment every three w****s with
pembrolizumab. In 2023, he
announced that the
pembrolizumab was
waning in
effectiveness and chemotherapy...
-
checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and
pembrolizumab.
Dendritic cell
therapy provokes anti-tumor
responses by
causing dendritic...
-
immunotherapy drugs blocking LAG3, B7-H3, KIR, OX40, PARP, CD27, and ICOS.
Pembrolizumab (Keytruda,
formerly MK-3475 and lambrolizumab) was
developed by Merck...
-
chemoresistant MSI-high
tumors can be
treated with
dostarlimab and
pembrolizumab. In the
European Union,
dostarlimab is
indicated as
monotherapy for...
-
treatment options.
Pembrolizumab monotherapy is an
appealing approach for
these patients, with
median OS of 30
months with
pembrolizumab single agent compared...
